Date: Sat, 24 Feb 2001 11:58:04 -0500
From: Michael Belkin
Subject: GlaxoSmithKline's Strong Performance from Key Therapy Areas and New
Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)
"Vaccines increased 11 percent to $1,280 million -- New vaccines,
accounting for 63 percent of the total vaccine portfolio, were up 20
percent, boosted by the performance of Infanrix, the company's DTPa
(diphtheria, tetanus and pertussis) range of combination vaccines --
growing at 47 percent." ...
Pharmaceutical sales by therapeutic area
2000
--------------------------------------------------------
Total
USA
Europe RoW
$m
CER% $m CER% $m CER% $m CER%
VACCINES 1,280 11 322
(5) 593 11
365 29
Hepatitis 702
(3) 255 (4)
319 (3) 128
(2)
Infanrix 260
47 53
59 149 34
58 84
http://biz.yahoo.com/prnews/010221/glaxosmithkline_earns.html
Content-Type: text/html; charset=iso-8859-1;
name="glaxosmithkline_earns.html"
Content-Disposition: inline;
filename="glaxosmithkline_earns.html"
Content-Base: "http://biz.yahoo.com/prnews/010221/gla
xosmithkline_earns.html"
Content-Location: "http://biz.yahoo.com/prnews/010221/gla
xosmithkline_earns.html"
Yahoo! Finance Finance Home - Yahoo! - Help
----------
PR Newswire
Click Here!
[ Latest Headlines | Market Overview | News Alerts ]
----------
Datek Online. Apply Now
Datek Online. Apply Now
Related Quotes
GSK
55.65
-0.84
delayed 20 mins - disclaimer
Wednesday February 21, 7:05 am Eastern Time
Press Release
SOURCE: GlaxoSmithKline plc
GlaxoSmithKline's Strong Performance from Key Therapy Areas and New
Products Drives Earnings Per Share Growth to 16% in Sterling (14% CER)
HIGHLIGHTS
- Pharmaceutical sales up 10 percent
- Sales growth in key therapy areas: CNS 16 percent, Respiratory 15
percent, Anti-virals 14 percent
- New products contributed nearly $1.5 billion in growth, up 60 percent
- Avandia sales of $702 million
- Seretide sales of $316 million, US launch of Seretide/Advair planned for
April 2001
- Business performance profits before tax up 11 percent; EPS up 14 percent
LONDON, Feb. 21 /PRNewswire/ -- GlaxoSmithKline plc (NYSE: GSK - news;
``GSK'') today announces its results for the year ended December 31, 2000,
summarized below. The merger of Glaxo Wellcome (``GW'') and SmithKline
Beecham (``SB'') was completed on December 27, 2000, and the results for
2000 reflect the combined results of the separate GW and SB businesses in
2000.
2000
BUSINESS PERFORMANCE RESULTS
2000
1999
Increase
$m
$m
CER%
Total Sales
27,480
26,186
9
Trading Profit
7,640
7,133
12
Profit Before Tax
8,097
7,627
11
Earnings Per ADR
$1.85
$1.71
14
Business performance results exclude merger items and restructuring costs.
Growth rates are at constant exchange rates (CER) unless otherwise stated.
1999 sales and trading profit exclude Healthcare Services.
Commenting on the performance for the year, Jean-Pierre Garnier, Chief
Executive Officer, said:
``These results, achieved while we were separate companies, demonstrate the
strength and performance of the two organizations we have brought together
to form GSK. Clearly our employees remained focused on maintaining the
momentum of our separate businesses, despite the distraction of integration
planning, and delivered excellent results. I'm particularly pleased by the
performance of Seretide and Avandia. The business is in good shape and GSK
is off to a strong start.''
Fourth quarter 2000 -- Sales growth in the fourth quarter was 4 percent,
essentially reflecting the impact of wholesaler stocking in the third
quarter in the USA. Key products, such as Paxil, Augmentin and Wellbutrin,
achieved significantly higher growth in prescription volume than in
reported sales, indicating that underlying business performance in the
fourth quarter remained strong.
Pharmaceuticals
Pharmaceutical sales of $23,452 million were 85 percent of total sales and
grew at 10 percent. With sales of over $4 billion, new products represent
17 percent of pharmaceutical sales and grew 60 percent.
Pharmaceutical sales in the USA, which represents half of GSK's total
pharmaceutical business, grew 15 percent driven by strong performances from
all major products. In Europe, pharmaceutical sales growth was 6 percent,
while the rest of the world (RoW) was up 8 percent.
Strong growth from key therapy areas: CNS growth driven by Seroxat/Paxil --
In GSK's largest sales category, CNS, excellent growth of 16 percent to
$4,984 million was driven by an outstanding performance from Seroxat/Paxil,
which increased by 17 percent to $2,356 million. During 2000, Paxil became
the market leader in the US SSRI (selective serotonin reuptake inhibitor)
market in new retail prescriptions. Paxil benefited throughout the world
from its new indication for Social Anxiety Disorder. GSK's strategy of
broadening the label for new indications continued with filings for
Generalized Anxiety Disorder and Post Traumatic Stress Disorder, and the
expected launches during 2001 will contribute to further growth of Paxil in
the USA. In Europe, where Seroxat continues to be the number one
antidepressant, its sales grew by 11 percent to $508 million, while in the
RoW growth was 29 percent to $242 million. Paxil was launched in Japan at
the end of 2000 and is off to a strong start.
Wellbutrin for depression also made a significant contribution to GSK's
strong CNS performance. In the USA, sales grew 19 percent, and worldwide
sales amounted to $687 million. In the company's migraine portfolio --
which achieved sales of $1,189 million, up 5 percent -- Imigran/Imitrex
remains the global market leader with sales of $1,072 million.
Lamictal for epilepsy grew strongly -- 28 percent to $439 million worldwide
and 34 percent in the USA to $210 million -- owing to additional
promotional resources in the USA.
Three key Respiratory products -- Seretide, Flixotide, and Serevent --
contributed $623 million in growth -- In the Respiratory therapy area,
Flixotide/Flovent, up 29 percent to $1,338 million, continues to be the
world's leading treatment for asthma. US sales growth of 57 percent
represents an outstanding performance. Seretide achieved sales of $316
million, and continues to be successfully launched in markets around the
world. Further Seretide growth will be driven by its US launch planned for
April under the trade name Advair. The company expects Seretide/Advair to
become the treatment of choice for persistent asthma.
Anti-viral leadership continued with the launch of Trizivir, the first
triple combination treatment for HIV/AIDS -- The growth of GSK's HIV
products, up 14 percent to $1,740 million, contributed strongly to the
performance of the company's Anti-viral therapy area. Combivir grew 21
percent to $854 million, while Trizivir, the first triple combination HIV
therapy, was launched in the USA in December 2000 and subsequently in the
UK, France and Switzerland. Strong performances from Ziagen and Agenerase,
with combined sales of over $300 million, reflect the broadness of the HIV
portfolio. In the herpes franchise, Valtrex, up 32 percent to $368 million,
gained significant market share owing to the convenience of its once-daily
dosing.
Confirmed success of Avandia drove the Metabolic & GI business -- Avandia
for the treatment of Type 2 diabetes continues to fulfill its outstanding
potential, achieving sales of $702 million. With sales in the US of $658
million and a 55 percent market share, Avandia has been prescribed to over
1.7 million patients. In 2001, further growth is expected from Avandia as
it continues to rollout in Europe and RoW. Lotronex, a treatment for
irritable bowel syndrome, was launched in the USA in March 2000 and
generated sales of $55 million before being withdrawn in November 2000.
Augmentin retained momentum in Anti-bacterials, with long-term
opportunities for growth -- The highlight of the performance in the Anti-
bacterial therapy area was Augmentin in the USA, where it grew by 13
percent to $1,102 million, benefiting from increased awareness of its
effectiveness in treating drug-resistant bacteria. Worldwide, Augmentin
achieved total sales in 2000 of $1,853 million, up 8 percent.
Vaccines increased 11 percent to $1,280 million -- New vaccines, accounting
for 63 percent of the total vaccine portfolio, were up 20 percent, boosted
by the performance of Infanrix, the company's DTPa (diphtheria, tetanus and
pertussis) range of combination vaccines -- growing at 47 percent.
Consumer Healthcare
Consumer Healthcare sales grew 3 percent; trading profit grew 7 percent --
In the USA, consumer sales decreased 3 percent, reflecting the impact of
private label smoking control products and a mild 'flu season.
Worldwide sales of Oral Care products rose 6 percent to $976 million, with
sales growth of 13 percent in the Aquafresh product line. Nutritional
Healthcare products increased 9 percent to $813 million. Sales growth was
primarily driven in the UK by the strength of Lucozade `Sport' and by the
success of Ribena. Worldwide sales of over-the-counter (OTC) medicines
totalled $2,210 million, down 1 percent primarily owing to an 8 percent
decline in the smoking control franchise.
Consumer Healthcare set to benefit from Block Drug acquisition -- In
January 2001, GSK completed the acquisition of Block Drug, the manufacturer
of Sensodyne toothpaste and other oral healthcare and consumer products,
for $1.24 billion. This strategic acquisition will enhance the Consumer
Healthcare performance through a significant increase in sales and sales
synergies through geographic expansion of major brands, significant cost
savings, and other improvements in trading margins.
Dividend
Both GW and SB had already announced dividends for the period up to 31st
December 2000. GW will pay a second interim dividend and SB a fourth
interim dividend on 17th April 2001.
GSK -- one of the world's leading research-based pharmaceutical and
healthcare companies -- is committed to improving the quality of human life
by enabling people to do more, feel better and live longer. For company
information, visit GSK on the World Wide Web at www.gsk.com.
Inquiries:
UK Media Inquiries
Martin
Sutton (020) 8966 8000
Philip
Thomson (020) 8966 8000
Alan
Chandler (020) 8975 2290
US Media Inquiries
Nancy
Pekarek (215) 751 7709
Mary
Anne Rhyne (919) 483 2839
European Analyst/Investor
Inquiries
Jennie
Younger (020) 8966 8378
Duncan
Learmouth (020) 8966 5961
Joan
Toohill (020) 8966 8715
Anita
Kidgell (020) 8966 8369
US Analyst/ Investor
Inquiries
Frank
Murdolo (212) 308 5185
Tom
Curry (215) 751 5419
GSK prepares its results in pounds sterling. Accordingly, the results
announcement is issued in pounds sterling and is available on ``Corporate
Home'' at www.gsk.com. This document is a convenience
translation in US$.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation
Reform Act of 1995, GSK cautions investors that any forward-looking
statements or projections made by GSK, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may affect
GSK's operations include generic and brand competition for existing
products, ability to integrate the businesses and realize synergies and
cost savings, difficulties and uncertainties inherent in new product
development, pricing pressures, changes in government laws and regulations,
efficacy or safety concerns over marketed products, adverse outcome of
material legal proceedings, changes in tax laws, and economic factors over
which GSK has no control including changes in inflation, interest rates and
foreign currency exchange rates and controls.
PROFIT AND LOSS ACCOUNT
2000
Merger,
restructuring
Business
and disposal of
performance
subsidiaries
Total
----------------------------------------------------
2000
1999 2000
1999 2000 1999
$m
$m CER% $m
$m $m
$m
-----
----- ----- ----- ----- -----
-----
SALES
Retained businesses
* Pharma-
ceuticals 23,452
22,061 10 -
- 23,452 22,061
* Consumer
Healthcare 4,028
4,125 3 -
- 4,028 4,125
------
------ ----- -----
------- -------
27,480
26,186 9 -
- 27,480 26,186
* Healthcare
Services
-
1,024
-
- -
1,024
-------
------- ----- ----- -------
-------
Total Sales 27,480
27,210 -
- 27,480 27,210
-------
------- ----- ----- -------
-------
Cost of sales (5,793) (5,669)
(8) (230) (646) (6,023) (6,315)
Selling,
general and
administration (10,232) (9,723) (9)
(614) (71) (10,846) (9,794)
Research and
development (3,815)
(3,702) (7) (24) -
(3,839) (3,702)
-------
------- ----- ----- -------
-------
Operating costs
- retained
businesses (19,840)
(19,094) (868) (717) (20,708) (19,811)
-------
------- ----- ----- -------
-------
Operating costs
- Healthcare
Services
-
(983)
- (49)
- (1,032)
TRADING PROFIT
Retained businesses
* Pharma-
ceuticals
6,963 6,436 13
(800) (685) 6,163 5,751
* Consumer
Healthcare
677 656
7 (68) (32) 609
624
-------
------- ----- ----- -------
-------
7,640
7,092 12 (868) (717)
6,772 6,375
* Healthcare
Services
-
41
- (49)
- (8)
-------
------- ----- ----- -------
-------
Total Trading
Profit
7,640
7,133 12 (868) (766)
6,772 6,367
Other operating
income/(expense) 416
669
-
- 416
669
-------
------- ----- ----- -------
-------
Operating profit 8,056 7,802
(868) (766) 7,188
7,036
Disposal of
associates
219
63
-
- 219
63
Profits/(losses)
of associates 99
24
(12) (13)
87 11
Divestments
-
-
2,131 15
2,131 15
Merger transaction
costs
-
-
(184) -
(184) -
-------
------- ----- ----- -------
-------
Profit before
interest
8,374
7,889 11 1,067 (764)
9,441 7,125
Net interest
payable
(277)
(262) -
- (277) (262)
-------
------- ----- ----- -------
-------
PROFIT BEFORE
TAXATION
8,097
7,627 11 1,067 (764)
9,164 6,863
Taxation
(2,210) (2,150)
(372) 176 (2,582)
(1,974)
-------
------- ----- ----- -------
-------
Profit after
taxation
5,887
5,477 12 695 (588)
6,582 4,889
Minority interests (183) (178)
- -
(183) (178)
Preference share
dividends
(85)
(79)
- -
(85) (79)
-------
------- ----- ----- -------
-------
EARNINGS
5,619
5,220 13 695 (588)
6,314 4,632
=======
======= ===== ===== =======
=======
EARNINGS PER ADR $1.85 $1.71
14
$2.08
$1.51
=======
=======
=======
=======
To illustrate ``Business performance'', merger items and restructuring
costs in 2000 and restructuring costs and business disposals in 1999 have
been excluded and an adjusted EPS presented.
Appropriations of profit attributable to shareholders are set out under
``Appropriations''.
PROFIT
AND LOSS ACCOUNT
Q4
2000
Merger,
restructuring
Business
and disposal of
performance
subsidiaries
Total
----------------------------------------------------
Q4
Q4
Q4 Q4
Q4 Q4
2000
1999 2000
1999 2000 1999
$m
$m CER% $m
$m $m
$m
-----
----- ----- ----- ----- -----
-----
SALES
Retained businesses
* Pharma-
ceuticals
6,319 6,388 5
- - 6,319
6,388
* Consumer
Healthcare 1,064
1,154 (1) -
- 1,064 1,154
------
------ ----- -----
------ ------
7,383
7,542 4 -
- 7,383 7,542
* Healthcare
Services
-
7
-
- -
7
------
------ ----- -----
------ ------
Total Sales 7,383
7,549
-
- 7,383 7,549
------
------ ----- -----
------ ------
Cost of sales (1,538) (1,612)
(1) (134) (271) (1,672) (1,883)
Selling,
general and
administration (2,726) (2,865)
2 (271) (29) (2,997) (2,894)
Research and
development (1,052)
(1,107) (2) (20) -
(1,072) (1,107)
------
------ ----- -----
------ ------
Operating costs
- retained
businesses (5,316)
(5,584) (425) (300) (5,741)
(5,884)
------
------ ----- -----
------ ------
Operating costs
- Healthcare
Services
-
(7)
- (39)
- (46)
TRADING PROFIT
Retained businesses
* Pharma-
ceuticals
1,858 1,786 14
(422) (274) 1,436 1,512
* Consumer
Healthcare
209 172
29 (3) (26) 206
146
------
------ ----- -----
------ ------
2,067
1,958 15 (425) (300)
1,642 1,658
* Healthcare
Services
-
-
- (39)
- (39)
------
------ ----- -----
------ ------
Total Trading
Profit
2,067
1,958 15 (425) (339)
1,642 1,619
Other operating
income/(expense) 222
310
-
- 222
310
------
------ ----- -----
------ ------
Operating profit 2,289 2,268
(425) (339) 1,864
1,929
Disposal of
associates
(3)
-
-
- (3)
-
Profits/(losses)
of associates 20
39
(1) (13)
19 26
Divestments
-
-
2,131 15
2,131 15
Merger transaction
costs
-
-
(113) -
(113) -
------
------ ----- -----
------ ------
Profit before
interest
2,306
2,307 9 1,592 (337)
3,898 1,970
Net interest
payable
(64)
(85)
- -
(64) (85)
------
------ ----- -----
------ ------
PROFIT BEFORE
TAXATION
2,242
2,222 10 1,592 (337)
3,834 1,885
Taxation
(612)
(619) (489)
58 (1,101) (561)
------
------ ----- -----
------ ------
Profit after
taxation
1,630
1,603 11 1,103 (279)
2,733 1,324
Minority interests (50)
(46)
- -
(50) (46)
Preference share
dividends
(22)
(21)
- -
(22) (21)
------
------ ----- -----
------ ------
EARNINGS
1,558
1,536 12 1,103 (279)
2,661 1,257
======
====== ===== =====
====== ======
EARNINGS PER ADR $0.51 $0.51
12
$0.88
$0.41
======
======
======
======
To illustrate ``Business performance'', merger items and restructuring
costs in 2000 and restructuring costs in 1999 have been excluded and an
adjusted EPS presented.
Pharmaceutical
sales by
therapeutic area
2000
--------------------------------------------------------
Total
USA
Europe
RoW
$m
CER% $m CER%
$m CER% $m CER%
------------
------------ ------------ -----------
CNS
4,984
16 3,507 15 1,031
16 446 28
Depression 3,043
17 2,272 18
508 11 263
31
Seroxat/Paxil 2,356 17
1,606 18 508
11 242 29
Wellbutrin 687
19 666 19
- -
21 58
Migraine 1,189
5 894
5 231 -
64 11
Imigran/Imitrex 1,072 3
824 4 193
(2) 55 6
Naramig/Amerge 117 20
70 20 38
15 9 51
Lamictal
439
28 210 34
176 20 53
35
Requip
88
20 40 19
46 20 2
26
Zyban
175
54 91
1 52 >100
32
23
RESPIRATORY 4,239
15 1,705 26 1,698
9 836 10
Flixotide/
Flovent 1,338
29 629 57
464 2 245
49
Serevent
945
8 502 24
385 (6) 58
14
Seretide
316 >100
- -
272 >100 44
>100
Flixonase/
Flonase
620
16 447 18
68 10 105
14
Ventolin
521
(7) 47 (21)
226 (5) 248 (6)
Becotide
312 (25)
6 (82) 231
(12) 75 (40)
ANTI-BACTERIALS 3,758 2
1,736 7 1,072 (4)
950 1
Augmentin 1,853
8 1,102 13
486 (3) 265
9
Zinnat/Ceftin 654
- 310 (7)
172 3 172
10
Fortum
324
(9) 61 (17)
134 (1) 129 (14)
Amoxil
302
1 79
55 93 (18)
130 -
ANTI-VIRALS 2,886
14 1,394 17
807 13 685
12
HIV
1,740
14 1,043 16
525 18 172
(9)
Trizivir
11
>100 9 >100
2 >100
- -
Combivir
854
21 524 17
263 38 67
(5)
Epivir
470
(7) 250 -
152 (9) 68
(22)
Retrovir
92
(30) 38 (22)
35 (35) 19 (33)
Ziagen
234
75 152 46
67 >100 15
>100
Agenerase
79 60
70 52
6 81
3
>100
Herpes
936
5 286 14
246 1 404
3
Valtrex
368
32 224 24
88 22 56
>100
Zovirax
568
(7) 62 (12)
158 (8) 348 (6)
Zeffix
106
>100 8 >100
10 >100
88 >100
Relenza
49
97 21 29
9 51 19
>100
METABOLIC &
GASTRO-
INTESTINAL 1,873
33 903 >100
377 (13) 593
3
Avandia
702
>100 658 >100
12 >100
32 >100
Zantac
874
(11) 181 (18) 287
(16) 406 (4)
Lotronex
55
>100 55 >100
- -
-
-
VACCINES 1,280
11 322 (5)
593 11 365
29
Hepatitis 702
(3) 255 (4)
319 (3) 128 (2)
Infanrix
260
47 53 59
149 34 58
84
ONCOLOGY &
EMESIS
1,079 11
758 12 196
9 125 10
Zofran
746
13 514 15
141 12 91
6
Hycamtin
144
1 96
(5) 35 6
13 40
CARDIOVASCULAR 704
- 429 (8)
182 19 93
10
Coreg
225
11 225 17
- -
- -
ARTHRITIS
(Relafen) 319
(28) 278 (30) 26
(7) 15 (23)
DERMATOLOGICALS 378 (4)
53 (20) 94
(5) 231 -
OTHER
1,272
(2) 260 (6)
346 (7) 666
2
-------------
------------- ------------ ------------
TOTAL SALES
CONTINUING
BUSINESS 22,772
11 11,345 15 6,422
6 5,005 9
Divested
products
680 (2)
367 (1) 65
(5) 248 (3)
Famvir
231
11 174 20
27 (13) 30
(5)
Kytril
333
(7) 187 (14)
38 1 108
2
Other
116
(9) 6 (40)
- - 110
(7)
-------------
------------- ------------ ------------
TOTAL
PHARMACEUTICAL
SALES
23,452 10
11,712 (3) 6,487 6
5,253 8
=============
============= ============ ============
Pharmaceutical
sales by therapeutic area
Q4
2000
--------------------------------------------------------
Total
USA
Europe
RoW
$m
CER% $m CER%
$m CER% $m CER%
------------
------------ ------------ -----------
CNS
1,337
5 931
1 276 7
130 31
Depression 801
3 583 (1)
137 - 81
45
Seroxat/Paxil 617
- 405 (5)
137 - 75
45
Wellbutrin 184
12 178 11
- -
6 48
Migraine
327
- 254
2 55 (10)
18 14
Imigran/Imitrex 296 -
236 2 45
(12) 15 11
Naramig/Amerge 31
4 18
4 10 (2)
3 42
Lamictal
120
20 61 26
45 14 14
16
Requip
25
3 12
6 14
1 (1) -
Zyban
53
76 22 (12)
21 >100 10
66
RESPIRATORY 1,185
14 502 25
448 7 235
9
Flixotide/
Flovent
391
28 205 64
113 (6) 73
36
Serevent
270
10 157 30
100 (8) 13
(1)
Seretide
114 >100
- -
93 >100 21
>100
Flixonase/
Flonase
152
5 113
5 14
4 25
4
Ventolin
142 (10)
16 (20) 58
(8) 68 (8)
Becotide
73
(34) (2) >(100) 57
(19) 18
(41)
ANTI-BACTERIALS 1,060 (7)
532 (3) 285 (12)
243 (9)
Augmentin 547
(2) 350 4
130 (12) 67
(6)
Zinnat/Ceftin 200
(4) 104 (9)
50 4 46
(2)
Fortum
82
(16) 15 (30)
32 (11) 35 (16)
Amoxil
76
(19) 16 3
25 (35) 35
(10)
ANTI-VIRALS 792
11 384 11
199 4 209
18
HIV
471
12 284 13
135 13 52
-
Trizivir
11
>100 9 >100
2 >100
- -
Combivir
233
18 141 16
70 23 22
16
Epivir
125
(3) 70 6
36 (7) 19
(20)
Retrovir
23
(22) 10 (16)
8 (26) 5
(27)
Ziagen
60
31 38 13
18 64 4
82
Agenerase
19
- 16 (11)
1 41 2
>100
Herpes
249
3 81
16 55 (8)
113 2
Valtrex
115
51 64 28
22 19 29
>100
Zovirax
134
(18) 17 (13)
33 (19) 84 (19)
Zeffix
34
>100 4 >100
2 >100
28 >100
Relenza
18
(23) 1 (93)
1 (76) 16
>100
METABOLIC & GASTRO-
INTESTINAL 501
23 238 86
95 (11) 168
2
Avandia
206
>100 187 >100
6 >100
13 >100
Zantac
224
(16) 42 (33)
70 (16) 112 (8)
Lotronex
6
>100 6 >100
- -
-
-
VACCINES
314
5 76
17 143 (8)
95 23
Hepatitis 165
(10) 61 7
73 (21) 31
(6)
Infanrix
67
20 14 88
37 12 16
8
ONCOLOGY & EMESIS 295 11
211 16 48
(2) 36
6
Zofran
198
13 138 18
35 6 25
3
Hycamtin
42
(1) 30 1
9 (11) 3
24
CARDIOVASCULAR 180 (3)
109 (12) 45
18 26 3
Coreg
59
23 59 23
- -
- -
ARTHRITIS (Relafen) 71 (31)
62 (30) 6
(40) 3 (31)
DERMATOLOGICALS 98 (5)
14 (17) 22
(2) 62 (3)
OTHER
336
8 72
26 90 (11)
174 16
------------
------------ ------------ ------------
TOTAL SALES
CONTINUING
BUSINESS 6,169
6 3,131 9
1,657 (1) 1,381 8
Divested
products
150 (26)
63 (40) 14
(18) 73 (11)
Famvir
45
(23) 32 (25)
5 (27) 8
(10)
Kytril
70
(32) 30 (51)
9 (11) 31
(8)
Other
35
(15) 1 (40)
- - 34
(14)
------------
------------ ------------ ------------
TOTAL
PHARMACEUTICAL
SALES
6,319
5 3,194 7
1,671 (1) 1,454 7
============
============ ============ ============
SOURCE: GlaxoSmithKline plc
Email this story - Most-emailed articles - Most-viewed articles
----------
More Quotes and News:GlaxoSmithKline PLC (NYSE:GSK -
news)
Related News Categories: earnings, medical/pharmaceutical
----------
Help
----------
Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of
Service
Copyright 2001 PR Newswire. All rights reserved. Republication or
redistribution of PRNewswire content is expressly prohibited without the
prior written consent of PRNewswire. PRNewswire shall not be liable for any
errors or delays in the content, or for any actions taken in reliance thereon.
Questions or Comments?